# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-173672
Filing Date
2026-04-23
Accepted
2026-04-23 16:06:01
Documents
19
Period of Report
2026-06-15

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | d64525ddef14a.htm iXBRL | DEF 14A | 1146312
3 | GRAPHIC | g64525g00a01.jpg | GRAPHIC | 49962
4 | GRAPHIC | g64525g01g43.jpg | GRAPHIC | 98494
5 | GRAPHIC | g64525g01g44.jpg | GRAPHIC | 65733
6 | GRAPHIC | g64525g01g69.jpg | GRAPHIC | 130809
7 | GRAPHIC | g64525g01g70.jpg | GRAPHIC | 130553
8 | GRAPHIC | g64525snap14.jpg | GRAPHIC | 4920
9 | GRAPHIC | g64525snap15.jpg | GRAPHIC | 9048
| Complete submission text file | 0001193125-26-173672.txt |  | 3067671

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL TAXONOMY EXTENSION SCHEMA | pcvx-20251231.xsd | EX-101.SCH | 6442
22 | EXTRACTED XBRL INSTANCE DOCUMENT | d64525ddef14a_htm.xml | XML | 258575

Mailing Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 650-837-0111
Vaxcyte, Inc. (Filer) CIK: 0001649094 (see all company filings)

EIN.: 464233385 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39323 | Film No.: 26888634
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)